US · Healthcare · Biotechnology
EPS came in at -0.61 against a street estimate of -0.53 — a miss of 15.1%.
Analysts rate Olema Pharmaceuticals Inc a strong buy (11 buy, 1 hold, 0 sell out of 12) with an average price target of $36.50.
| Fund | Stake |
|---|---|
| FMR Inc | 13.88% |
| Paradigm Biocapital Advisors LP | 9.91% |
| HHG PLC | 8.12% |
| Jupiter Topco LLC | 8.11% |
| Bain Capital Life Sciences Investors, LLC | 8.10% |
| BlackRock Inc | 7.67% |
| Bvf Inc | 6.05% |
| Siren, L.L.C. | 5.55% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 OLEMA PHARMACEUTICALS, INC. - 8-K SUMMARY HEADLINE NUMBERS • New CFO Appointment: Jason O'Byrne appointed as Chief Financial Officer effective Augus | 2026-08-13 |
| Quarterly report · Q2 2026 OLEMA PHARMACEUTICALS, INC. – 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash & Securities Position: $461.1 million (cash $48.6M + marketable securit | 2026-08-10 |
| Results announced · Q3 2026 OLEMA ONCOLOGY Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash, cash equivalents, and marketable securities: $461.1 million as of June 30, 2026 • | 2026-08-10 |
| Shareholder vote results · Q2 2026 OLEMA PHARMACEUTICALS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held June 17, 2026 • Four Class III directors elected to ser | 2026-06-23 |
| Reg FD disclosure · Q2 2026 OLEMA PHARMACEUTICALS 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Olema Pharmaceuticals announced a clinical trial collaboration and supply agreemen | 2026-05-26 |
| Quarterly report · Q1 2026 OLEMA PHARMACEUTICALS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $52.5 million in cash + $452.8 million in marketable securities | 2026-05-12 |
| Proxy statement · Q2 2026 OLEMA PHARMACEUTICALS, INC. – 2026 PROXY SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1 – Election of Directors: Vote to elect four Class | 2026-04-29 |
| Annual report FY2025 OLEMA PHARMACEUTICALS, INC. — 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: Olema Pharmaceuticals, Inc. (ticker: OLMA, Nasdaq) • Fis | 2026-03-16 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Olema Pharmaceuticals Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.